Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
Mar 2023COVID-19
Dec 2022Non-Alcoholic Steatohepatitis
Apr 2023Menopause: Vasomotor Symptoms
Dec 2022Sickle Cell Disease
Jun 2023Featured News & Insights.
Learn about our latest work.
ICER Publishes Final Evidence Report on Fezolinetant for Vasomotor Symptoms Associated with Menopause
Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit for fezolinetant when compared to no pharmacological treatment.
01/23/2023ICER Publishes Second Annual Assessment of Barriers to Fair Access Within US Commercial Insurance Prescription Drug Coverage
During ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change.
01/17/2023ICER Releases Draft Evidence Report on Treatments for Alzheimer’s Disease
Public comment period now open until February 2, 2023; Requests to make oral comment during public meeting also being accepted
12/22/2022Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Latest
Developments.
We recently celebrated our 15th anniversary! Learn more.
We recently published a commentary in Health Affairs about one-time treatments like Zynteglo and Hemgenix. In both of these ICER reports, we analyzed a “shared savings” scenario, which suggests how manufacturers of these one-time therapies, instead of capturing all the avoided downstream medical costs in one giant price tag, could set a lower price and therefore share the innovation windfall with society. Read the full article here.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.
Current
Policy Papers.
Easy access to our latest policy papers
Barriers to Fair Access
Second annual scorecard of barriers to fair access criteria; during ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change
Unsupported Price Increases
Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.
Additionally, three Medicare Part B drugs with high list price increases in 2020 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $3,200 per year.
Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.